Pierpaoli W
Clin Exp Immunol. 1985 Jan;59(1):210-6.
Haemopoietic radiation chimeras across the H-2 barrier (BALB/c----C57Bl/6; H-2d----H-2b chimeras and vice versa) have been studied for their capacity to suppress the growth, or to reject, transplantable B16 melanotic melanoma and radiation leukaemia virus-induced, transplantable leukaemia. Also, radiation leukaemia virus (RadLV) obtained from the thymus of leukaemic C57Bl/6 mice was injected i.p. into established chimeras (H-2d----H-2b). As expected, long lived, graft versus host disease free allogeneic chimeras constructed with intact bone marrow were unable to reject the tumours both when recipients were BALB/c----C57Bl/6 or C57Bl/6----BALB/c chimeras. However, also inoculation of a large number of immunocompetent cells from normal BALB/c mice into BALB/c----C57Bl/6 chimeras, failed to promote a rejection of the tumours. On the contrary, the same amount of syngeneic (BALB/c) immunocompetent cells prevented growth of melanoma when transferred into athymic nude BALB/c mice, while the tumour grew unimpaired in untreated athymic nude BALB/c mice. The same type of H-2d----H-2b chimeras displayed complete resistance to inculation of leukaemogenic H-2b restricted RadLV while all H-2b----H-2b, syngeneically reconstituted mice developed disseminated leukaemia. These findings demonstrate that: (a) a powerful suppressive principle operates in the chimeras which does not allow effector function and anti-tumour activity of passively transferred normal, mature T cells from resistant BALB/c mice. Thus, no H-2 restriction of donor T cells can be advocated for suppression of anti-tumour effector functions in the chimeras. (b) New donor (BALB/c, H-2d) marrow character in the H-2d----H-2b chimeras prevents expression of the H-2b restricted viral activity and leukaemogenic transformation and/or proliferation.
已对跨越H-2屏障的造血辐射嵌合体(BALB/c→C57Bl/6;H-2d→H-2b嵌合体,反之亦然)进行研究,以了解其抑制可移植B16黑色素瘤生长或排斥该肿瘤以及辐射白血病病毒诱导的可移植白血病的能力。此外,将从白血病C57Bl/6小鼠胸腺中获得的辐射白血病病毒(RadLV)腹腔注射到已建立的嵌合体(H-2d→H-2b)中。正如预期的那样,用完整骨髓构建的长期存活、无移植物抗宿主病的同种异体嵌合体,无论是受体为BALB/c→C57Bl/6嵌合体还是C57Bl/6→BALB/c嵌合体,都无法排斥肿瘤。然而,将大量来自正常BALB/c小鼠的免疫活性细胞接种到BALB/c→C57Bl/6嵌合体中,也未能促进肿瘤的排斥。相反,相同数量的同基因(BALB/c)免疫活性细胞转移到无胸腺裸BALB/c小鼠中时可阻止黑色素瘤生长,而在未处理的无胸腺裸BALB/c小鼠中肿瘤则不受影响地生长。相同类型的H-2d→H-2b嵌合体对致白血病的H-2b限制性RadLV接种表现出完全抗性,而所有同基因重建的H-2b→H-2b小鼠都发生了播散性白血病。这些发现表明:(a)嵌合体中存在一种强大的抑制机制,不允许来自抗性BALB/c小鼠的被动转移的正常成熟T细胞发挥效应功能和抗肿瘤活性。因此,不能主张供体T细胞的H-2限制用于抑制嵌合体中的抗肿瘤效应功能。(b)H-2d→H-2b嵌合体中的新供体(BALB/c,H-2d)骨髓特征可阻止H-2b限制性病毒活性的表达以及白血病转化和/或增殖。